In fiscal year 2025, iNtRON Biotechnology (048530) reported revenue of 5.7 billion KRW.
Income Statement
| Year | Revenue | Op Profit | Net Income | Source |
|---|
| 2025 | 5.7 billion KRW | -7.9 billion KRW | -9.0 billion KRW | [source] |
| 2024 | 6.4 billion KRW | -5.2 billion KRW | -2.6 billion KRW | [source] |
| 2023 | 9.6 billion KRW | -3.3 billion KRW | -9.7 billion KRW | [source] |
| 2022 | 14.0 billion KRW | -1.5 billion KRW | 5.7 billion KRW | [source] |
| 2021 | 29.3 billion KRW | 10.1 billion KRW | 9.7 billion KRW | [source] |
Balance Sheet
| Year | Total Assets | Total Liabilities | Total Equity | Source |
|---|
| 2025 | 74.1 billion KRW | 4.4 billion KRW | 69.7 billion KRW | [source] |
| 2024 | 86.0 billion KRW | 2.5 billion KRW | 83.5 billion KRW | [source] |
| 2023 | 98.2 billion KRW | 1.8 billion KRW | 96.4 billion KRW | [source] |
| 2022 | 141.6 billion KRW | 34.7 billion KRW | 106.9 billion KRW | [source] |
| 2021 | 154.1 billion KRW | 52.0 billion KRW | 102.1 billion KRW | [source] |
Cash Flow
| Year | Operating | Investing | Financing | Source |
|---|
| 2025 | — | 1.5 billion KRW | -2.9 billion KRW | [source] |
| 2024 | — | 3.1 billion KRW | -9.8 billion KRW | [source] |
| 2023 | 3.1 billion KRW | 52.2 billion KRW | -40.2 billion KRW | [source] |
| 2022 | 6.0 billion KRW | -46.2 billion KRW | -9.2 billion KRW | [source] |
| 2021 | 16.5 billion KRW | -41.3 billion KRW | 39.7 billion KRW | [source] |
Cash flow figures for the relevant year were not collected.
